Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035

globenewswire.com
NVS Novartis is mentioned as a market participant exploring growth opportunities in the biosimilars market, indicating potential involvement and interest in the sector's expansion. PFE Pfizer is listed as a market participant actively exploring new avenues for growth within the expanding biosimilars market. AMGN Amgen is identified as a key player in the biosimilars market, continuously seeking growth opportunities and involved in the competitive landscape.

Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035 Dublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab and Etanercept Biosimilars Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The adalimumab, infliximab, and etanercept biosimilars market is experiencing substantial growth, escalating from $4.96 billion in 2025 to an estimated $5.47 billion in 2026, with a projected CAGR of 10.3%. Driving this growth are factors such as the high prevalence of autoimmune diseases, advances in biosimilar research, cost barriers associated with original biologics, and favorable governmental policies. This momentum is further expected to propel the market to $8.05 billion by 2030, supported by advancements in precision medicine, increased healthcare spending, and adoption of digital health solutions.

The surge in autoimmune diseases significantly boosts biosimilar demand. Johns Hopkins University, in 2023, noted that about 3% of the U.S. population suffers from such conditions, creating urgent demand for TNF-alpha inhibiting treatments like adalimumab, infliximab, and etanercept. These biologics offer effective solutions for chronic inflammatory diseases, fueling the preference for biosimilars that offer cost-effective alternatives.

Technological advancements are key, with companies like Celltrion USA introducing products such as Yuflyma, a high-concentration, citrate-free biosimilar, enhancing patient experience while maintaining therapeutic effectiveness. Such innovations underscore the competitive landscape, ensuring patient compliance and reduced discomfort.

Strategic mergers, such as Celltrion's acquisition of iQone Healthcare in 2024, highlight the ongoing market consolidation. This move aims at strengthening European biosimilar commercialization, expanding distribution networks, and elevating treatment access. Market participants such as Biogen, Novartis, Pfizer, Amgen, and others are continuously exploring new horizons to harness growth opportunities.

Regionally, North America led the market in 2025, with significant activity anticipated across Asia-Pacific, Europe, and beyond. This geographical spread underlines the global reach and potential for biosimilar therapies. Tariffs, while posing cost challenges, inspire localized production, thereby bolstering regional market resilience.

The adalimumab, infliximab, and etanercept biosimilars market encompasses a wide array of products, with leading offerings like Amgevita, Hyrimoz, and Idacio distributed via diverse channels including hospital, retail, and online pharmacies. This market growth reflects in enterprise revenues across specified geographies, extending beyond traditional boundaries and ensuring extensive market penetration.

Comprehensive market reports provide vital insights into global trends, segments, and innovation opportunities, furnishing stakeholders with the necessary data to thrive in this evolving industry landscape.

Report Scope

Key Attributes:

Major Trends

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/qexf0

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment